• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Appoints Janet Choi, M.D., as Chief Medical Officer

    4/4/23 9:00:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of Janet Choi, M.D., as the company's Chief Medical Officer.

    Dr. Choi brings more than 20 years of experience in the field as a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology. In her new role, she will lead clinical strategy working closely with the company's executive team and medical advisory board to ensure Progyny offers the highest quality and most effective family building and women's health benefits possible.

    "I am thrilled to officially join the Progyny family after having worked alongside this incredible team for more than three years on the medical advisory board and seeing firsthand how they redefine what a fertility and family building benefit should be," said Dr. Choi. "As a physician in the Progyny network, I have seen how an inclusive and comprehensive employer-sponsored benefit empowers patients and providers to make the best clinical decisions resulting in healthier pregnancies and babies. Growing one's family should not be considered a luxury and I am eager to increase access to high-quality family building care."

    "We are excited to have Dr. Choi join Progyny in her new role as Chief Medical Officer where she will provide her unparalleled knowledge as a distinguished fertility and reproductive health specialist, and further our industry-defining work in the benefits space," said Pete Anevski, CEO of Progyny. "Together with Dr. Choi, we look forward to pioneering new and innovative solutions to some of today's largest hurdles in women's health."

    Prior to Progyny, Dr. Choi was the Medical Director of CCRM New York for the last 7 years. Before CCRM, she was an assistant clinical professor in Obstetrics and Gynecology at Columbia University Medical Center and served as the Director of Onco-fertility and Co-Director of the Fertility Preservation Program. Dr. Choi is board-certified in both Obstetrics and Gynecology and in Reproductive Endocrinology, and has written, published, and lectured extensively on infertility, onco-fertility, and fertility preservation. She is an active member of the American Society for Reproductive Medicine (ASRM), the American College of Obstetricians and Gynecologists (ACOG), as well as the New York Obstetrical Society. She has been selected as one of New York Magazine's Top Doctors as well as a New York Super Doctor annually since 2018; a Castle Connolly Exceptional Woman in Medicine every year since 2019; and has been annually listed with Castle Connolly's "Top Doctors" since 2015.

    Dr. Choi graduated Magna Cum Laude from Harvard University with an A.B. in English literature and earned her medical degree and completed her residency in Obstetrics and Gynecology at Columbia University. She completed her sub-specialty fellowship in Reproductive Endocrinology and Infertility at Weill Cornell Medical College in New York.

    About Progyny

    Progyny (NASDAQ:PGNY) is a leading fertility benefits management company. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians.

    Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation's leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For Further Information, Please Contact:

    Investors:

    James Hart

    [email protected]

    Media:

    Selena Yang

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    7/8/2025$28.00Market Perform → Outperform
    Leerink Partners
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Progyny upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Progyny from Sector Weight to Overweight and set a new price target of $30.00

    11/12/25 8:53:41 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Progyny from Market Perform to Outperform and set a new price target of $28.00

    7/8/25 11:08:47 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny downgraded by Analyst with a new price target

    Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

    12/2/24 10:07:08 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $PGNY
    SEC Filings

    View All

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Schlanger David J covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.85% to 220,419 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    10/2/25 4:26:50 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 7,977 shares, decreasing direct ownership by 1% to 539,564 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    10/2/25 4:24:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    EVP, GC Swartz Allison sold $14,094 worth of shares (599 units at $23.53) and covered exercise/tax liability with 339 shares, decreasing direct ownership by 1% to 77,407 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    9/5/25 4:39:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by Progyny Inc.

    10-Q - Progyny, Inc. (0001551306) (Filer)

    11/7/25 9:06:49 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Progyny, Inc. (0001551306) (Filer)

    11/6/25 4:14:16 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.

    SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)

    11/5/25 11:44:46 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Third Quarter 2025 Results

    Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2025 ("the third quarter of 2025"), as compared to the th

    11/6/25 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2025 after the close of the market on Thursday, November 6, 2025. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcod

    10/23/25 1:08:44 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause

    NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the launch of its pregnancy, postpartum, and menopause programs for global employers, available starting January 1, 2026. These offerings complement the availability of the company's existing and marketing-leading global fertility and family building offering, providing multi-national employers with a continuum of integrated services. Progyny's localized global expertise and member-first experience are supporting unmet needs across pivotal women's and family life stages. Global employers are recognizing the need to offer specialized care

    10/22/25 9:28:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:35:03 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:31:32 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    View All

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

    NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

    5/14/25 9:05:48 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

    NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

    4/17/25 9:36:59 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    11/14/24 4:31:23 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    2/14/24 6:29:49 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Financials

    Live finance-specific insights

    View All

    Progyny, Inc. Announces Third Quarter 2025 Results

    Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2025 ("the third quarter of 2025"), as compared to the th

    11/6/25 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2025 after the close of the market on Thursday, November 6, 2025. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcod

    10/23/25 1:08:44 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Second Quarter 2025 Results

    Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended June 30, 2025 ("the second quarter of 2025") as compared to the three-month period ended June 30, 2024 ("the second quarter of 2024" or "the prior year period"). "The strong second quarter results

    8/7/25 4:02:43 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care